Jens Juul Holst1. 1. NNF Center for Basic Metabolic Research and Department of Biomedical Sciences, The Panum Institute, Faculty of Health Sciences, University of Copenhagen, Blegdamsvej 3, Copenhagen N, Denmark.
Abstract
PURPOSE OF REVIEW: Among the gastrointestinal hormones, the incretins: glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 have attracted interest because of their importance for the development and therapy of type 2 diabetes and obesity. New agonists and formulations of particularly the GLP-1 receptor have been developed recently showing great therapeutic efficacy for both diseases. RECENT FINDINGS: The status of the currently available GLP-1 receptor agonists (GLP-1RAs) is described, and their strengths and weaknesses analyzed. Their ability to also reduce cardiovascular and renal risk is described and analysed. The most recent development of orally available agonists and of very potent monomolecular co-agonists for both the GLP-1 and GIP receptor is also discussed. SUMMARY: The GLP-1RAs are currently the most efficacious agents for weight loss, and show potential for further efficacy in combination with other food-intake-regulating peptides. Because of their glycemic efficacy and cardiorenal protection, the GLP-1 RAs will be prominent elements in future diabetes therapy.
PURPOSE OF REVIEW: Among the gastrointestinal hormones, the incretins: glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 have attracted interest because of their importance for the development and therapy of type 2 diabetes and obesity. New agonists and formulations of particularly the GLP-1 receptor have been developed recently showing great therapeutic efficacy for both diseases. RECENT FINDINGS: The status of the currently available GLP-1 receptor agonists (GLP-1RAs) is described, and their strengths and weaknesses analyzed. Their ability to also reduce cardiovascular and renal risk is described and analysed. The most recent development of orally available agonists and of very potent monomolecular co-agonists for both the GLP-1 and GIP receptor is also discussed. SUMMARY: The GLP-1RAs are currently the most efficacious agents for weight loss, and show potential for further efficacy in combination with other food-intake-regulating peptides. Because of their glycemic efficacy and cardiorenal protection, the GLP-1 RAs will be prominent elements in future diabetes therapy.
Authors: D Liu; J Flory; A Lin; M Offin; C J Falcon; Y R Murciano-Goroff; E Rosen; R Guo; E Basu; B T Li; J J Harding; G Iyer; K Jhaveri; M M Gounder; N N Shukla; S S Roberts; J Glade-Bender; L Kaplanis; A Schram; D M Hyman; A Drilon Journal: Ann Oncol Date: 2020-05-15 Impact factor: 32.976
Authors: Deborah A Goldspink; Van B Lu; Emily L Miedzybrodzka; Christopher A Smith; Rachel E Foreman; Lawrence J Billing; Richard G Kay; Frank Reimann; Fiona M Gribble Journal: Cell Rep Date: 2020-06-30 Impact factor: 9.423
Authors: Anna K O Rode; Terkild Brink Buus; Veronika Mraz; Fatima Abdul Hassan Al-Jaberi; Daniel Villalba Lopez; Shayne L Ford; Stephanie Hennen; Ina Primon Eliasen; Ib Vestergaard Klewe; Leila Gharehdaghi; Adrian Dragan; Mette M Rosenkilde; Anders Woetmann; Lone Skov; Niels Ødum; Charlotte M Bonefeld; Martin Kongsbak-Wismann; Carsten Geisler Journal: Cells Date: 2022-08-19 Impact factor: 7.666
Authors: Seunghun P Lee; Jenson Qi; Guozhang Xu; Matthew M Rankin; James Littrell; June Zhi Xu; Ivona Bakaj; Alessandro Pocai Journal: Front Endocrinol (Lausanne) Date: 2021-05-14 Impact factor: 5.555